Targeting a 2 million-strong patient market in the U.S., startup GT Urological is developing an implantable fake sphincter that can help men control incontinence. The Minneapolis company just raised $5 million, according to a regulatory filing.
The company’s developed an implantable prosthesis called the Phenix Artificial Urinary Sphincter, which treats moderate to severe male stress urinary incontinence – a common issue that follows prostate cancer surgery. It’s under clinical investigation in Europe.
Outside of behavioral modifications and muscle control exercises, there isn’t much available for incontinence treatment. The development process for GT Urological has been slow-going, but would prove to be a unique alternative to a fairly widespread issue in men.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Since its launch in 2003, GT Urological’s raised $2.5 million in SBIR funding and $11 million in private equity.
